These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 21134724)

  • 41. Medicare program: Medicare Advantage and prescription drug programs MIPPA drug formulary & protected classes policies. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2009 Jan; 74(11):2881-8. PubMed ID: 19385109
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Medicare program; Medicare Advantage and prescription drug benefit programs. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2011 Sep; 76(170):54600-35. PubMed ID: 21894660
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Can a pharmacist reduce annual costs for Medicare Part D enrollees?
    Alston G; Hanrahan C
    Consult Pharm; 2011 Mar; 26(3):182-9. PubMed ID: 21402518
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
    Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
    Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PDPs see increases in cost-sharing amounts.
    Manag Care; 2009 Aug; 18(8):55. PubMed ID: 19731513
    [No Abstract]   [Full Text] [Related]  

  • 46. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
    Patel RA; Walberg MP; Tong E; Tan F; Rummel AE; Woelfel JA; Carr-Lopez SM; Galal SM
    J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Examining the impact of Part D on nursing home residents.
    Hudson N
    Find Brief; 2010 May; 13(4):1-3. PubMed ID: 21121179
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
    [No Abstract]   [Full Text] [Related]  

  • 49. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
    Polinski JM; Mohr PE; Johnson L
    Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Access to cancer drugs in Medicare Part D: formulary placement and beneficiary cost sharing in 2006.
    Bowman J; Rousseau A; Silk D; Harrison C
    Health Aff (Millwood); 2006; 25(5):1240-8. PubMed ID: 16966719
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulations regarding income-related monthly adjustment amounts to Medicare beneficiaries' prescription drug coverage premiums. Interim final rule with request for comments.
    Social Security Administration
    Fed Regist; 2010 Dec; 75(234):75884-96. PubMed ID: 21137594
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Understanding the Medicare Part D prescription program: partnerships for beneficiaries and health care professionals.
    De Natale ML
    Policy Polit Nurs Pract; 2007 Aug; 8(3):170-81. PubMed ID: 18178923
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Navigating Medicare drug coverage: Part B vs. Part D.
    Piper KB
    Manag Care; 2006 Jul; 15(7 Suppl 3):17-20. PubMed ID: 16898056
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Will the Medicare prescription drug benefit eliminate cost barriers for older adults with diabetes mellitus?
    Tjia J; Schwartz JS
    J Am Geriatr Soc; 2006 Apr; 54(4):606-12. PubMed ID: 16686870
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of prescription coverage on hospital and physician costs: a case study of medicare beneficiaries with chronic obstructive pulmonary disease.
    Stuart B; Doshi JA; Briesacher B; Wrobel MV; Baysac F
    Clin Ther; 2004 Oct; 26(10):1688-99. PubMed ID: 15598486
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Medicare Part D doughnut hole: effect on pharmacy utilization.
    Sun SX; Lee KY
    Manag Care Interface; 2007 Sep; 20(9):51-5, 59. PubMed ID: 18161394
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Closing the Medicare Doughnut Hole: Changes in Prescription Drug Utilization and Out-of-Pocket Spending Among Medicare Beneficiaries With Part D Coverage After the Affordable Care Act.
    Bonakdar Tehrani A; Cunningham PJ
    Med Care; 2017 Jan; 55(1):43-49. PubMed ID: 27547949
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of Medicare Part D and insurance type on Medicare beneficiary access to prescription medication and use of prescription cost-saving measures.
    Urmie JM; Farris KB; Doucette WR; Goedken AM
    J Am Pharm Assoc (2003); 2011; 51(1):72-81. PubMed ID: 21247829
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of satisfaction and switching costs in Medicare Part D choices.
    Han J; Ko DW; Urmie JM
    Res Social Adm Pharm; 2014; 10(2):398-407. PubMed ID: 23988694
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
    Shaw DL; Dhruva SS; Ross JS
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.